E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Nervous System Diseases [C10] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 19.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10015052 |
E.1.2 | Term | Epileptic seizure |
E.1.2 | System Organ Class | 100000004852 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate the efficacy of USL261 compared with that of IN placebo for the outpatient treatment of seizure clusters based on Treatment Success, which is defined as achieving both of the following: •Termination of seizure(s) within 10 minutes after study drug administration, and •No recurrence of seizure(s) beginning 10 minutes after study drug administration to 6 hours after study drug administration Refer to protocol for further objectives.
|
|
E.2.2 | Secondary objectives of the trial |
To evaluate the efficacy of USL261 compared with that of IN placebo for the outpatient treatment of seizure clusters using the following: •Proportion of subjects with recurrence of seizure(s) beginning 10 minutes after study drug administration to 4 hours after study drug administration •Time to next seizure with a start time > 10 minutes after study drug administration Refer to protocol for further objectives.
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
•Subject or subject's legally acceptable representative (LAR) has provided written informed consent, and subject has provided written assent where required by local law or Institutional Review Board/Independent Ethics Committee policy •Subject has a competent, adult caregiver who can recognize and observe the subject's seizure cluster episodes •Subject is 12 years of age or older, at Visit 1 •Subject has an established diagnosis of partial or generalized epilepsy that includes all of the following: - A documented history of seizure clusters lasting a minimum of 10 minutes from the time the seizure cluster is recognized - The seizure cluster pattern is observable, stereotyped, and recognizably different from the subject's other non-cluster seizure activity (if any) in seizure type, duration, severity or frequency - As part of the subject's stereotyped seizure cluster pattern, a second seizure typically occurs within 6 hours from the time of recognition of the seizure cluster - In the investigator's opinion, it would be safe for the subject to receive placebo as a first dose of study drug followed by active treatment (USL261) as the second dose of study drug no earlier than 10 minutes after the first dose - The subject's stereotyped seizure cluster pattern is composed of multiple (≥2) partial or generalized seizures - The subject's stereotyped seizure cluster pattern was established > 3 months before Visit 1 - A frequency of ≥3 stereotyped seizure clusters during the year before Visit 1 - At least 1 stereotyped seizure cluster occurring ≤4 months before Visit 1 - The seizure cluster pattern described above is confirmed by a central reviewer •Currently on a stable regimen of AEDs since Visit 1 and for ≥7 days before Visit 2.
|
|
E.4 | Principal exclusion criteria |
•Subject has a neurological disorder that is likely to progress in the next year •Subject has had psychogenic, non-epileptic seizure(s) within the 5 years before Visit 1 •Subject has a history of their stereotypical seizure cluster progressing to status epilepticus (as determined by the investigator) within the 2 years before Visit 1 •Subject has acute narrow-angle glaucoma. •Subject has had an active suicidal plan/intent or active suicidal thoughts in the 6 months before Visit 1 as defined by a Columbia-Suicide Severity Rating Scale (C-SSRS) suicidal ideation score ≥3, any suicide attempt in the past 5 years as determined by the C-SSRS or medical history, or other clinically significant suicidality as determined by the investigator •Subject is currently using a vagal nerve stimulator (VNS) unless the device has been implanted for at least 6 months and the settings have not changed within 4 weeks before Visit 1.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary efficacy endpoint is the proportion of subjects who meet the criteria for Treatment Success. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Treatment Success is a composite measure of efficacy that will be assessed based upon the first seizure cluster treated during the Comparative Phase. Treatment Success is defined as achieving the following: •Termination of seizure(s) within 10 minutes after study drug administration, and •No recurrence of seizure(s) beginning 10 minutes after administration of study drug to 6 hours after study drug administration
|
|
E.5.2 | Secondary end point(s) |
•Proportion of subjects with recurrence of seizure(s) beginning 10 minutes after administration of study drug to 4 hours after administration of study drug •Time to next seizure with a start time > 10 minutes after study drug administration
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
•Proportion of subjects with recurrence of seizure(s): beginning 10 minutes after administration of study drug to 4 hours after administration of study drug •Time to next seizure with a start time > 10 minutes after study drug administration
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | Yes |
E.8.1.7.1 | Other trial design description |
open-label test-dose phase, followed by double-blind comparative phase |
|
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 6 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 25 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Australia |
Canada |
European Union |
Israel |
New Zealand |
Ukraine |
United States |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 4 |
E.8.9.1 | In the Member State concerned months | 8 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 5 |
E.8.9.2 | In all countries concerned by the trial months | 8 |
E.8.9.2 | In all countries concerned by the trial days | 0 |